
    
      Phase II study for treatment of patients with relapsed or primary refractory aggressive B-
      cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for
      autologous stem cell transplantation. Aim is to find response rates and duration of
      combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory CD
      20 positive B cell NHL.
    
  